Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion

Vera Therapeutics (VERA) Financials

Vera Therapeutics logo
$34.04 -0.31 (-0.90%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$34.11 +0.07 (+0.20%)
As of 05/22/2026 06:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Vera Therapeutics

Annual Income Statements for Vera Therapeutics

This table shows Vera Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -53 -33 -89 -96 -152 -300
Consolidated Net Income / (Loss)		 -53 -33 -89 -96 -152 -300
Net Income / (Loss) Continuing Operations		 -53 -33 -89 -96 -152 -300
Total Pre-Tax Income 		-53 -33 -89 -96 -152 -300
Total Operating Income		 -52 -34 -91 -102 -167 -315
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 52 34 91 102 167 315
Selling, General & Admin Expense		 4.04 12 22 24 41 100
Research & Development Expense		 45 22 69 78 126 215
Total Other Income / (Expense), net		 -1.17 1.79 1.85 6.02 15 16
Interest Expense		 0.17 0.02 0.99 3.79 7.63 7.53
Interest & Investment Income		 0.01 0.02 1.75 7.98 21 24
Other Income / (Expense), net		 -1.01 1.80 1.09 1.83 1.94 -1.09
Income Tax Expense		 -0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($166.93) ($2.43) ($3.35) ($2.25) ($2.75) ($4.66)
Weighted Average Basic Shares Outstanding		 319.96K 13.44M 26.57M 42.71M 55.33M 64.23M
Diluted Earnings per Share		 ($166.93) ($2.43) ($3.35) ($2.25) ($2.75) ($4.66)
Weighted Average Diluted Shares Outstanding		 319.96K 13.44M 26.57M 42.71M 55.33M 64.23M
Weighted Average Basic & Diluted Shares Outstanding		 319.96K 13.44M 44.26M 54.45M 0.00 71.36M

Quarterly Income Statements for Vera Therapeutics

This table shows Vera Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -20 -26 -28 -34 -47 -43 -52 -77 -80 -91 -121
Consolidated Net Income / (Loss)		 -20 -26 -28 -34 -47 -43 -52 -77 -80 -91 -121
Net Income / (Loss) Continuing Operations		 -20 -26 -28 -34 -47 -43 -52 -77 -80 -91 -121
Total Pre-Tax Income 		-20 -26 -28 -34 -47 -43 -52 -77 -80 -91 -121
Total Operating Income		 -22 -27 -31 -37 -50 -49 -57 -80 -84 -94 -125
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 22 27 31 37 50 49 57 80 84 94 125
Selling, General & Admin Expense		 5.66 6.24 7.91 8.03 9.49 16 16 22 27 35 39
Research & Development Expense		 16 21 23 29 40 33 41 58 56 59 86
Total Other Income / (Expense), net		 1.65 1.37 2.73 3.64 3.17 5.49 5.50 3.61 3.64 3.11 4.10
Interest Expense		 0.94 1.06 1.91 1.91 1.94 1.87 1.79 1.87 1.96 1.91 1.82
Interest & Investment Income		 2.16 1.96 4.19 5.10 4.76 6.66 6.91 6.32 5.74 5.52 6.36
Other Income / (Expense), net		 0.44 0.47 0.45 0.44 0.34 0.70 0.39 -0.84 -0.14 -0.50 -0.43
Basic Earnings per Share		 ($0.45) ($0.54) ($0.56) ($0.62) ($0.85) ($0.72) ($0.81) ($1.20) ($1.26) ($1.39) ($1.69)
Weighted Average Basic Shares Outstanding		 44.36M 42.71M 50.97M 54.73M 54.90M 55.33M 63.67M 63.79M 63.85M 64.23M 71.48M
Diluted Earnings per Share		 ($0.45) ($0.54) ($0.56) ($0.62) ($0.85) ($0.72) ($0.81) ($1.20) ($1.26) ($1.39) ($1.69)
Weighted Average Diluted Shares Outstanding		 44.36M 42.71M 50.97M 54.73M 54.90M 55.33M 63.67M 63.79M 63.85M 64.23M 71.48M
Weighted Average Basic & Diluted Shares Outstanding		 44.43M 54.45M 54.70M 54.83M 63.32M 0.00 63.77M 63.82M 63.93M 71.36M 71.78M

Annual Cash Flow Statements for Vera Therapeutics

This table details how cash moves in and out of Vera Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 19 26 -36 1.93 47 262
Net Cash From Operating Activities		 -35 -24 -68 -92 -135 -241
Net Cash From Continuing Operating Activities		 -66 -24 -68 -92 -135 -241
Net Income / (Loss) Continuing Operations		 -53 -33 -89 -96 -152 -300
Consolidated Net Income / (Loss)		 -53 -33 -89 -96 -152 -300
Depreciation Expense		 0.25 0.18 -0.85 0.02 0.11 0.47
Amortization Expense		 - - - -4.11 -8.16 -5.12
Non-Cash Adjustments To Reconcile Net Income		 18 1.21 13 11 20 39
Changes in Operating Assets and Liabilities, net		 0.12 7.51 9.35 -3.18 5.07 24
Net Cash From Investing Activities		 -0.04 -4.20 -71 -39 -425 194
Net Cash From Continuing Investing Activities		 -0.04 -4.20 -71 -39 -425 194
Purchase of Property, Plant & Equipment		 -0.10 -5.00 -0.06 -0.06 -0.97 -0.63
Purchase of Investments		 - 0.00 -148 -225 -703 -310
Sale and/or Maturity of Investments		 - 0.00 78 186 279 506
Other Investing Activities, net		 - - - 0.00 0.00 -0.80
Net Cash From Financing Activities		 85 54 102 134 607 309
Net Cash From Continuing Financing Activities		 86 54 102 134 607 309
Repayment of Debt		 -0.02 4.92 - 25 0.00 0.00
Repurchase of Common Equity		 0.00 -2.77 - 0.00 -0.01 0.00
Issuance of Debt		 5.60 - - 0.00 0.00 23
Issuance of Common Equity		 0.00 52 88 116 646 307
Other Financing Activities, net		 0.10 0.00 14 -7.26 -39 -21
Cash Interest Paid		 0.03 0.02 0.90 3.35 6.65 6.72

Quarterly Cash Flow Statements for Vera Therapeutics

This table details how cash moves in and out of Vera Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -6.45 18 23 -44 2.17 65 -38 -5.97 8.65 297 -240
Net Cash From Operating Activities		 -23 -25 -34 -25 -37 -39 -54 -55 -62 -70 -107
Net Cash From Continuing Operating Activities		 -23 -25 -34 -25 -37 -39 -54 -55 -62 -70 -107
Net Income / (Loss) Continuing Operations		 -20 -26 -28 -34 -47 -43 -52 -77 -80 -91 -121
Consolidated Net Income / (Loss)		 -20 -26 -28 -34 -47 -43 -52 -77 -80 -91 -121
Depreciation Expense		 0.01 0.00 0.01 1.50 0.02 0.06 0.09 0.12 0.13 0.14 0.14
Amortization Expense		 -3.09 -1.17 -1.48 - -6.70 -1.85 -2.31 -1.73 -0.61 -0.47 -0.20
Non-Cash Adjustments To Reconcile Net Income		 5.11 3.75 4.64 1.54 11 6.77 8.95 10 8.80 11 28
Changes in Operating Assets and Liabilities, net		 -4.90 -2.08 -8.62 5.51 5.86 -0.73 -9.44 13 10 10 -14
Net Cash From Investing Activities		 16 19 -219 -23 38 -221 15 29 70 81 -138
Net Cash From Continuing Investing Activities		 16 19 -219 -23 38 -221 15 29 70 81 -138
Purchase of Property, Plant & Equipment		 - -0.06 0.00 - -0.24 -0.65 -0.19 -0.21 -0.13 -0.10 -0.02
Purchase of Investments		 -29 -53 -255 -81 -73 -294 -90 -97 -99 -24 -211
Sale and/or Maturity of Investments		 45 72 36 59 112 73 106 126 169 105 88
Other Investing Activities, net		 - - 0.00 - - - -0.75 -0.05 - - -15
Net Cash From Financing Activities		 0.30 25 277 3.44 0.74 326 1.53 20 0.80 286 3.94
Net Cash From Continuing Financing Activities		 0.30 25 277 3.44 0.74 326 1.53 20 0.80 286 3.94
Repurchase of Common Equity		 - - 0.00 - - - 0.00 - - - 0.00
Issuance of Debt		 - - - - - - 0.00 - - - 0.00
Issuance of Common Equity		 0.30 0.09 294 3.44 0.75 347 1.53 0.46 0.80 304 3.94
Other Financing Activities, net		 - - -18 - - -21 0.00 -3.52 - -18 0.00
Cash Interest Paid		 0.86 0.85 1.52 1.73 1.74 1.66 1.58 1.66 1.77 1.72 1.63

Annual Balance Sheets for Vera Therapeutics

This table presents Vera Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 55 84 131 176 656 735
Total Current Assets		 54 83 126 172 651 729
Cash & Equivalents		 54 80 43 46 93 355
Short-Term Investments		 - 0.00 71 115 548 360
Prepaid Expenses		 0.56 2.86 11 11 10 14
Plant, Property, & Equipment, net		 0.00 0.00 0.05 0.09 0.96 0.00
Total Noncurrent Assets		 0.29 1.21 5.69 3.43 3.50 5.85
Other Noncurrent Operating Assets		 0.29 0.34 5.63 3.43 3.50 5.85
Total Liabilities & Shareholders' Equity		 55 84 131 176 656 735
Total Liabilities		 4.33 14 55 74 79 130
Total Current Liabilities		 2.41 7.69 26 22 25 53
Accounts Payable		 0.91 1.39 12 11 7.67 22
Accrued Expenses		 0.54 5.93 11 8.75 16 32
Total Noncurrent Liabilities		 1.92 6.47 29 52 53 77
Long-Term Debt		 - 4.92 25 50 51 75
Other Noncurrent Operating Liabilities		 0.29 0.29 4.12 1.68 2.47 1.92
Total Equity & Noncontrolling Interests		 -89 70 77 102 577 605
Total Preferred & Common Equity		 -89 70 77 102 577 605
Total Common Equity		 -89 70 77 102 577 605
Common Stock		 2.10 194 290 410 1,038 1,365
Retained Earnings		 -91 -124 -213 -309 -461 -761
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.22 0.25 0.39 0.79

Quarterly Balance Sheets for Vera Therapeutics

This table presents Vera Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 131 210 195 176 419 397 369 610 579 518 622
Total Current Assets		 125 204 191 172 416 395 364 606 571 511 616
Cash & Equivalents		 30 137 34 27 69 25 27 55 49 58 114
Short-Term Investments		 84 60 147 132 335 359 326 535 508 440 482
Prepaid Expenses		 11 7.30 9.59 12 13 10 11 16 15 14 19
Plant, Property, & Equipment, net		 0.06 0.05 0.04 0.03 0.08 0.16 0.37 1.06 1.15 1.16 0.00
Total Noncurrent Assets		 6.33 5.11 4.52 3.96 2.91 2.39 4.06 3.03 6.02 5.04 5.94
Other Noncurrent Operating Assets		 6.21 5.05 4.50 3.95 2.91 2.39 4.06 3.03 6.02 5.04 5.94
Total Liabilities & Shareholders' Equity		 131 210 195 176 419 397 369 610 579 518 622
Total Liabilities		 26 52 55 52 66 69 80 75 110 119 122
Total Current Liabilities		 16 24 27 25 15 18 26 22 34 42 45
Accounts Payable		 7.01 5.33 13 12 5.21 4.66 4.60 9.26 13 18 14
Accrued Expenses		 6.22 16 11 9.80 7.06 12 20 11 20 23 31
Total Noncurrent Liabilities		 9.73 28 28 27 51 51 53 53 77 77 77
Long-Term Debt		 4.97 25 25 25 50 50 50 51 74 75 75
Other Noncurrent Operating Liabilities		 4.77 3.48 2.86 2.25 1.21 0.74 2.57 2.37 2.23 2.10 1.86
Total Equity & Noncontrolling Interests		 106 158 141 124 354 328 289 535 468 399 500
Total Preferred & Common Equity		 106 158 141 124 354 328 289 535 468 399 500
Total Common Equity		 106 158 141 124 354 328 289 535 468 399 500
Common Stock		 287 401 404 407 691 700 706 1,047 1,057 1,068 1,382
Retained Earnings		 -181 -243 -263 -283 -337 -371 -418 -513 -589 -670 -882
Accumulated Other Comprehensive Income / (Loss)		 -0.28 -0.00 -0.14 -0.08 -0.17 -0.45 1.04 0.65 0.53 0.88 -0.16

Annual Metrics And Ratios for Vera Therapeutics

This table displays calculated financial ratios and metrics derived from Vera Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 38.82% -179.58% -15.01% -66.20% -85.36%
EBIT Growth		 0.00% 38.78% -175.47% -11.55% -64.93% -91.58%
NOPAT Growth		 0.00% 34.15% -164.24% -12.22% -63.87% -88.71%
Net Income Growth		 0.00% 38.95% -173.10% -7.79% -58.50% -96.92%
EPS Growth		 0.00% 98.54% -37.86% 32.84% -22.22% -69.45%
Operating Cash Flow Growth		 0.00% 31.89% -185.12% -36.37% -46.10% -79.02%
Free Cash Flow Firm Growth		 0.00% 0.00% -163.17% -32.79% -50.39% -75.51%
Invested Capital Growth		 0.00% -73.36% -115.62% 29.55% -42.12% -170.79%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 45.16% -22.30% 2.50% -17.38% -16.31%
EBIT Q/Q Growth		 0.00% 44.39% -21.51% 5.81% -15.08% -17.22%
NOPAT Q/Q Growth		 0.00% 43.02% -23.00% 6.04% -15.06% -16.76%
Net Income Q/Q Growth		 0.00% 44.39% -21.22% 6.60% -13.22% -18.92%
EPS Q/Q Growth		 0.00% 98.35% -140.26% 22.15% -7.00% -16.79%
Operating Cash Flow Q/Q Growth		 0.00% 46.91% -27.85% -4.51% -11.64% -14.65%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -14.00% -9.61% -14.17% -10.93%
Invested Capital Q/Q Growth		 0.00% -229.65% -236.78% 18.29% 5.59% -47.65%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.30% 100.02% 99.16% 95.81% 92.08% 94.65%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -106.34% -54.43% -121.58% -107.50% -44.83% -50.71%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 189.16% 8.97% -121.55% -107.45% -44.82% -50.71%
Return on Equity Simple (ROE_SIMPLE)		 59.78% -46.86% -115.80% -94.40% -26.36% 0.00%
Net Operating Profit after Tax (NOPAT)		 -37 -24 -64 -71 -117 -221
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -31.37% -13.19% -30.72% -24.49% -10.02% -12.81%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -47.12% -18.64% -32.51%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -53 -33 -90 -100 -165 -317
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -53 -32 -91 -104 -173 -321
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 8.17 6.96 6.72 4.64 5.36
Price to Tangible Book Value (P/TBV)		 0.00 8.17 6.96 6.72 4.64 5.36
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.07 0.32 0.49 0.09 0.12
Long-Term Debt to Equity		 0.00 0.07 0.32 0.49 0.09 0.12
Financial Leverage		 -1.07 -1.08 -1.13 -1.12 -1.03 -1.04
Leverage Ratio		 1.09 1.15 1.47 1.72 1.22 1.18
Compound Leverage Factor		 1.09 1.15 1.46 1.65 1.13 1.11
Debt to Total Capital		 0.00% 6.61% 24.39% 32.91% 8.07% 11.02%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 6.61% 24.39% 32.91% 8.07% 11.02%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 277.88% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -177.88% 93.39% 75.58% 67.06% 91.93% 88.98%
Debt to EBITDA		 0.00 -0.15 -0.27 -0.48 -0.29 -0.23
Net Debt to EBITDA		 0.00 2.33 0.99 1.06 3.41 1.99
Long-Term Debt to EBITDA		 0.00 -0.15 -0.27 -0.48 -0.29 -0.23
Debt to NOPAT		 0.00 -0.20 -0.39 -0.70 -0.43 -0.34
Net Debt to NOPAT		 0.00 3.14 1.41 1.55 5.04 2.90
Long-Term Debt to NOPAT		 0.00 -0.20 -0.39 -0.70 -0.43 -0.34
Altman Z-Score		 2.21 21.81 2.28 2.23 19.79 13.15
Noncontrolling Interest Sharing Ratio		 277.88% 116.49% 0.02% 0.04% 0.01% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 22.55 10.73 4.91 7.71 25.67 13.64
Quick Ratio		 22.30 10.36 4.48 7.21 25.26 13.37
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -22 -57 -75 -113 -199
Operating Cash Flow to CapEx		 -82,878.57% -474.16% -109,025.81% -146,319.05% -13,855.86% -38,270.48%
Free Cash Flow to Firm to Interest Expense		 0.00 -1,076.57 -57.12 -19.88 -14.84 -26.37
Operating Cash Flow to Interest Expense		 -209.69 -1,185.40 -68.14 -24.35 -17.66 -32.01
Operating Cash Flow Less CapEx to Interest Expense		 -209.95 -1,435.40 -68.20 -24.36 -17.79 -32.10
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -3.48 -6.03 -13 -9.15 -13 -35
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.55 -6.97 3.84 -3.86 -22
Enterprise Value (EV)		 134 493 445 573 2,088 2,598
Market Capitalization		 48 569 535 683 2,678 3,237
Book Value per Share		 ($279.24) $3.27 $2.78 $2.29 $9.11 $9.46
Tangible Book Value per Share		 ($279.24) $3.27 $2.78 $2.29 $9.11 $9.46
Total Capital		 50 75 102 152 628 679
Total Debt		 0.00 4.92 25 50 51 75
Total Long-Term Debt		 0.00 4.92 25 50 51 75
Net Debt		 -54 -76 -90 -111 -590 -640
Capital Expenditures (CapEx)		 0.04 5.00 0.06 0.06 0.97 0.63
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.85 -4.83 -15 -11 -15 -39
Debt-free Net Working Capital (DFNWC)		 52 75 100 150 626 675
Net Working Capital (NWC)		 52 75 100 150 626 675
Net Nonoperating Expense (NNE)		 17 8.53 25 25 35 79
Net Nonoperating Obligations (NNO)		 -54 -76 -90 -111 -590 -640
Total Depreciation and Amortization (D&A)		 0.25 0.18 -0.85 -4.09 -8.06 -4.66
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.43) ($3.35) ($2.25) ($2.75) ($4.66)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 27.05M 26.57M 42.71M 55.33M 64.23M
Adjusted Diluted Earnings per Share		 $0.00 ($2.43) ($3.35) ($2.25) ($2.75) ($4.66)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 27.05M 26.57M 42.71M 55.33M 64.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.43) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.44M 44.26M 54.45M 0.00 71.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -34 -24 -64 -71 -117 -221
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -320.81 -1,630.15 -90.54 -26.46 -21.67 -42.03
NOPAT to Interest Expense		 -220.29 -1,204.07 -64.15 -18.86 -15.34 -29.32
EBIT Less CapEx to Interest Expense		 -321.06 -1,880.15 -90.60 -26.48 -21.79 -42.12
NOPAT Less CapEx to Interest Expense		 -220.55 -1,454.07 -64.21 -18.88 -15.47 -29.41
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -8.48% 0.00% 0.00% -0.01% 0.00%

Quarterly Metrics And Ratios for Vera Therapeutics

This table displays calculated financial ratios and metrics derived from Vera Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 71,355,667.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 71,355,667.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.70
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 3.36% 16.82% -2.58% -68.84% -130.03% -80.38% -83.72% -109.13% -63.67% -90.06% -112.81%
EBIT Growth		 15.06% 18.86% 0.50% -71.73% -131.99% -81.55% -85.27% -119.45% -69.98% -96.43% -121.03%
NOPAT Growth		 13.82% 19.51% 0.47% -69.97% -128.91% -80.98% -83.83% -114.61% -68.53% -92.60% -118.79%
Net Income Growth		 18.54% 20.91% 5.61% -67.19% -131.95% -69.27% -82.13% -127.04% -72.18% -109.78% -134.13%
EPS Growth		 50.55% 54.24% 30.00% -34.78% -88.89% -33.33% -44.64% -93.55% -48.24% -93.06% -108.64%
Operating Cash Flow Growth		 -24.72% -18.82% -28.67% -39.44% -60.56% -55.83% -60.82% -121.12% -67.84% -78.64% -95.75%
Free Cash Flow Firm Growth		 49.59% -37.60% -87.10% -531.91% -309.46% -33.50% 0.48% -36.16% -50.77% -43.91% -92.14%
Invested Capital Growth		 -190.38% 29.55% 99.62% 59.81% -23.01% -42.12% -6,912.50% -125.20% -73.14% -170.79% -461.09%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -16.37% -13.62% -15.90% -10.19% -58.54% 10.91% -18.04% -39.91% -2.37% -12.42% -32.18%
EBIT Q/Q Growth		 0.78% -24.57% -15.46% -20.34% -34.03% 2.51% -17.82% -42.55% -3.82% -12.66% -32.58%
NOPAT Q/Q Growth		 0.97% -24.23% -15.11% -20.03% -33.36% 1.78% -16.93% -40.12% -4.73% -12.24% -32.83%
Net Income Q/Q Growth		 0.29% -27.61% -10.63% -18.76% -38.34% 6.88% -19.04% -48.05% -4.92% -13.46% -32.86%
EPS Q/Q Growth		 2.17% -20.00% -3.70% -10.71% -37.10% 15.29% -12.50% -48.15% -5.00% -10.32% -21.58%
Operating Cash Flow Q/Q Growth		 -29.27% -9.45% -34.55% 26.75% -48.84% -6.23% -38.85% -0.72% -12.97% -13.07% -52.16%
Free Cash Flow Firm Q/Q Growth		 -40.54% -188.66% -59.66% 2.44% 8.93% 5.88% -19.03% -33.47% -0.84% 10.17% -58.92%
Invested Capital Q/Q Growth		 28.02% 18.29% 99.39% -11,069.64% -120.32% 5.59% 69.82% -258.70% -69.40% -47.65% 37.46%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 94.30% 96.60% 92.56% 91.35% 94.29% 90.06% 91.00% 94.51% 95.51% 96.19% 96.39%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -89.59% -107.50% -36.89% -46.05% -65.11% -44.83% -39.49% -54.83% -73.25% -50.71% -71.32%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -89.59% -107.45% -36.89% -46.05% -65.10% -44.82% -39.49% -54.83% -73.24% -50.71% -71.32%
Return on Equity Simple (ROE_SIMPLE)		 -83.08% 0.00% -26.67% -32.89% -46.49% 0.00% -32.80% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 -19 -22 -26 -35 -34 -40 -56 -59 -66 -88
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.99% -6.71% -2.51% -3.09% -5.38% -2.62% -2.61% -5.00% -5.94% -4.09% -6.31%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.48% - - - -5.45% -6.83% -10.34% -12.41% -9.71% -15.24%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -21 -27 -31 -37 -49 -48 -57 -81 -84 -95 -126
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -28 -32 -35 -56 -50 -59 -83 -85 -95 -126
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.91 6.72 6.64 6.04 8.39 4.64 2.86 3.21 4.65 5.36 5.74
Price to Tangible Book Value (P/TBV)		 4.91 6.72 6.64 6.04 8.39 4.64 2.86 3.21 4.65 5.36 5.74
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.20 0.49 0.14 0.15 0.17 0.09 0.10 0.16 0.19 0.12 0.15
Long-Term Debt to Equity		 0.20 0.49 0.14 0.15 0.17 0.09 0.10 0.16 0.19 0.12 0.15
Financial Leverage		 -1.07 -1.12 -1.03 -1.05 -1.06 -1.03 -1.00 -1.03 -1.05 -1.04 -1.03
Leverage Ratio		 1.34 1.72 1.23 1.26 1.32 1.22 1.16 1.23 1.29 1.18 1.19
Compound Leverage Factor		 1.26 1.66 1.14 1.16 1.24 1.10 1.05 1.16 1.23 1.13 1.15
Debt to Total Capital		 16.84% 32.91% 12.40% 13.29% 14.86% 8.07% 8.69% 13.72% 15.76% 11.02% 13.05%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 16.84% 32.91% 12.40% 13.29% 14.86% 8.07% 8.69% 13.72% 15.76% 11.02% 13.05%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 83.16% 67.06% 87.60% 86.71% 85.12% 91.93% 91.31% 86.28% 84.24% 88.98% 86.95%
Debt to EBITDA		 -0.23 -0.48 -0.48 -0.42 -0.34 -0.29 -0.25 -0.31 -0.27 -0.23 -0.19
Net Debt to EBITDA		 1.26 1.06 3.37 2.80 2.05 3.41 2.69 1.98 1.53 1.99 1.35
Long-Term Debt to EBITDA		 -0.23 -0.48 -0.48 -0.42 -0.34 -0.29 -0.25 -0.31 -0.27 -0.23 -0.19
Debt to NOPAT		 -0.33 -0.70 -0.70 -0.61 -0.50 -0.43 -0.38 -0.45 -0.39 -0.34 -0.28
Net Debt to NOPAT		 1.78 1.55 4.96 4.07 2.98 5.04 3.98 2.92 2.24 2.90 1.94
Long-Term Debt to NOPAT		 -0.33 -0.70 -0.70 -0.61 -0.50 -0.43 -0.38 -0.45 -0.39 -0.34 -0.28
Altman Z-Score		 5.37 3.61 21.19 16.63 17.36 20.38 11.89 7.40 8.12 14.15 12.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.04% 0.00% 0.00% 0.01% 0.01% 0.00% 0.00% 0.01% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.97 7.71 28.63 21.43 13.76 25.67 27.68 17.03 12.21 13.64 13.64
Quick Ratio		 6.50 7.21 27.76 20.87 13.35 25.26 26.94 16.60 11.88 13.37 13.22
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.88 -23 -36 -35 -32 -30 -36 -48 -49 -44 -69
Operating Cash Flow to CapEx		 0.00% -39,911.11% 0.00% 0.00% -15,497.90% -6,074.73% -29,094.12% -26,345.19% -46,545.86% -68,621.57% -463,043.48%
Free Cash Flow to Firm to Interest Expense		 -8.36 -21.57 -19.06 -18.54 -16.67 -16.23 -20.18 -25.76 -24.83 -22.95 -38.12
Operating Cash Flow to Interest Expense		 -24.36 -23.83 -17.75 -12.96 -19.05 -20.93 -30.36 -29.24 -31.58 -36.74 -58.42
Operating Cash Flow Less CapEx to Interest Expense		 -24.36 -23.89 -17.75 -12.96 -19.18 -21.28 -30.46 -29.35 -31.65 -36.80 -58.43
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -11 -9.15 -0.06 -6.26 -14 -13 -3.93 -14 -24 -35 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -7.35 3.84 15 9.31 -2.58 -3.86 -3.87 -7.83 -10 -22 -18
Enterprise Value (EV)		 473 573 1,994 1,645 2,121 2,088 992 1,020 1,432 2,598 2,349
Market Capitalization		 608 683 2,348 1,979 2,423 2,678 1,531 1,503 1,855 3,237 2,871
Book Value per Share		 $2.79 $2.29 $6.49 $5.99 $5.27 $9.11 $8.39 $7.34 $6.25 $9.46 $7.00
Tangible Book Value per Share		 $2.79 $2.29 $6.49 $5.99 $5.27 $9.11 $8.39 $7.34 $6.25 $9.46 $7.00
Total Capital		 149 152 404 378 340 628 586 543 474 679 575
Total Debt		 25 50 50 50 50 51 51 74 75 75 75
Total Long-Term Debt		 25 50 50 50 50 51 51 74 75 75 75
Net Debt		 -135 -111 -354 -334 -303 -590 -539 -482 -423 -640 -522
Capital Expenditures (CapEx)		 0.00 0.06 0.00 0.00 0.24 0.65 0.19 0.21 0.13 0.10 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -11 -1.84 -8.06 -16 -15 -5.65 -19 -28 -39 -26
Debt-free Net Working Capital (DFNWC)		 147 150 402 376 338 626 584 538 469 675 571
Net Working Capital (NWC)		 147 150 402 376 338 626 584 538 469 675 571
Net Nonoperating Expense (NNE)		 4.87 6.74 6.60 7.57 12 9.19 12 20 22 25 33
Net Nonoperating Obligations (NNO)		 -135 -111 -354 -334 -303 -590 -539 -482 -423 -640 -522
Total Depreciation and Amortization (D&A)		 -3.08 -1.17 -1.47 1.50 -6.68 -1.79 -2.23 -1.62 -0.48 -0.34 -0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.54) ($0.56) ($0.62) ($0.85) ($0.72) ($0.81) ($1.20) ($1.26) ($1.39) ($1.69)
Adjusted Weighted Average Basic Shares Outstanding		 44.36M 42.71M 50.97M 54.73M 54.90M 55.33M 63.67M 63.79M 63.85M 64.23M 71.48M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.54) ($0.56) ($0.62) ($0.85) ($0.72) ($0.81) ($1.20) ($1.26) ($1.39) ($1.69)
Adjusted Weighted Average Diluted Shares Outstanding		 44.36M 42.71M 50.97M 54.73M 54.90M 55.33M 63.67M 63.79M 63.85M 64.23M 71.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 44.43M 54.45M 54.70M 54.83M 63.32M 0.00 63.77M 63.82M 63.93M 71.36M 71.78M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -19 -22 -26 -35 -34 -40 -56 -59 -66 -88
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -22.61 -25.17 -16.09 -19.30 -25.55 -25.76 -31.70 -43.21 -42.89 -49.72 -68.88
NOPAT to Interest Expense		 -16.15 -17.93 -11.43 -13.67 -18.01 -18.29 -22.34 -29.94 -29.98 -34.62 -48.05
EBIT Less CapEx to Interest Expense		 -22.61 -25.23 -16.09 -19.30 -25.67 -26.10 -31.81 -43.32 -42.96 -49.77 -68.89
NOPAT Less CapEx to Interest Expense		 -16.15 -17.99 -11.43 -13.67 -18.13 -18.64 -22.45 -30.05 -30.04 -34.67 -48.06
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% -0.01% -0.01% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, investor-focused view of Vera Therapeutics (VERA) based on the company’s quarterly statements over the last several years. Vera appears to be in a pre-revenue phase with ongoing losses, but has actively raised capital to fund operations.

  • The company has strong access to capital, with large equity financing contributing meaningfully to liquidity (Net Cash From Financing Activities: about $325.96 million in Q4 2024 and about $286.28 million in Q4 2025).
  • Significant cash inflows from the sale/maturity of investments in 2025 bolster liquidity (Q3 2025: $168.59 million; Q4 2025: $105.27 million).
  • Balance-sheet liquidity looks solid on a near-term basis, with current assets around $511 million and current liabilities around $41.9 million in Q3 2025, implying a substantial near-term liquidity cushion.
  • Cash balances have fluctuated quarter-to-quarter but generally remain in the mid-to-high tens of millions, indicating some stability in liquidity despite ongoing cash burn.
  • The company has no revenue, with Total Revenue reported as zero in multiple periods (e.g., 2025 Q1–Q4 and many prior quarters), limiting top-line growth prospects.
  • Ongoing net losses are substantial and have trended higher in 2025 (Net Income Attributable to Common Shareholders around $91.1 million in Q4 2025 and $80.3 million in Q3 2025).
  • Operating cash flow is negative in every quarter of 2025 (Net Cash From Continuing Operating Activities: roughly -$69.99 million in Q4 2025, -$61.91 million in Q3 2025, -$54.80 million in Q2 2025, -$54.41 million in Q1 2025).
  • R&D and SG&A expenses remain high and rising (Q4 2025 RD expense about $59.31 million; SG&A about $34.90 million; total operating expenses about $94.21 million), signaling continued investment with no revenue yet.
  • Reliance on equity financing creates dilution risk; large equity issuances (e.g., Q4 2024 and Q4 2025) dilute existing shareholders unless offset by future profitability.
  • Total equity declined through 2025 due to losses (Total Common Equity fell from roughly $535 million in early 2025 to about $399 million by Q3 2025; Retained Earnings are negative), signaling rising balance-sheet leverage relative to earnings power.
05/23/26 02:32 AM ETAI Generated. May Contain Errors.

Vera Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Vera Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Vera Therapeutics' net income appears to be on an upward trend, with a most recent value of -$299.62 million in 2025, rising from -$53.41 million in 2020. The previous period was -$152.15 million in 2024. See Vera Therapeutics' forecast for analyst expectations on what's next for the company.

Vera Therapeutics' total operating income in 2025 was -$315.47 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $315.47 million

Over the last 5 years, Vera Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Vera Therapeutics' total liabilities were at $130.21 million at the end of 2025, a 65.8% increase from 2024, and a 2,910.0% increase since 2020.

In the past 5 years, Vera Therapeutics' cash and equivalents has ranged from $43.46 million in 2022 to $354.73 million in 2025, and is currently $354.73 million as of their latest financial filing in 2025.

Over the last 5 years, Vera Therapeutics' book value per share changed from -279.24 in 2020 to 9.46 in 2025, a change of -103.4%.


Related Companies

Financial statements for NASDAQ:VERA last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
The AI stocks about to become worthless (and one that isn't)
Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...
InvestorPlace | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel